Resources

Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 25 July 2025.

The Modified Monash (MM) fact sheet for category MM 1 covers metropolitan areas.

The Modified Monash (MM) fact sheet for category MM 2 covers regional areas.

The Modified Monash (MM) fact sheet for category MM 3 covers rural towns.

The Modified Monash (MM) fact sheet for category MM 4 covers medium rural towns.

The Modified Monash (MM) fact sheet for category MM 5 covers small rural towns.

The Modified Monash (MM) fact sheet for category MM 6 covers remote communities.

The Modified Monash (MM) fact sheet for category MM 7 covers very remote communities.

Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 6 March 2025.

This report outlines the Avalglucosidase alfa 24 Month Review Terms of Reference and Protocol Questions

Life Saving Drugs Program (LSDP) Expert Panel (the panel) agenda for the 17th meeting on 13 December 2024.

Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.